NCT02616211View on ClinicalTrials.gov

An Integrated Approach to Treating Recurrent Thoracic Carcinomas Resistant to Tyrosine Kinase Inhibitors

CompletedOBSERVATIONAL
Enrollment

15

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

October 31, 2018

Study Completion Date

December 31, 2019

Conditions
Adenocarcinoma of LungLung NeoplasmCancer of LungLung CancerPulmonary CancerEGFR GenesALK Genes
Trial Locations (1)

55905

Mayo Clinic in Rochester, Rochester

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
collaborator

National Foundation for Cancer Research

OTHER

lead

Mayo Clinic

OTHER

NCT02616211 - An Integrated Approach to Treating Recurrent Thoracic Carcinomas Resistant to Tyrosine Kinase Inhibitors | Biotech Hunter | Biotech Hunter